RxDoctor Payments Data

David Rosenblum Donath, MD

Internal Medicine · Boynton Beach, FLNPI 1457658569

Payments from drug & device makers

$351in general payments, 2019–2025

Across 18 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$98
  • Pfizer$78
  • Astellas Pharma US Inc$47
  • Novartis$40
  • GSK$40
  • Boehringer Ingelheim$19
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$351 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$28,457
Medicare patients
70
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$137,729
JardianceEmpagliflozin87$117,394
OzempicSemaglutide45$68,490
XareltoRivaroxaban25$36,053
EntrestoSacubitril/Valsartan23$31,146
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,341
Tresiba Flextouch U-100Insulin Degludec19$16,399
SymbicortBudesonide/Formoterol Fumarate48$16,273
MyrbetriqMirabegron16$16,236
Breo ElliptaFluticasone/Vilanterol19$9,789
InvokanaCanagliflozin12$9,188
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$5,456
CreonLipase/Protease/Amylase12$5,153
Rosuvastatin Calcium591$3,957
Levothyroxine Sodium460$3,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$137,729128 claims
Boehringer IngelheimJardiance$19$117,39487 claims
Novo NordiskOzempic$98$68,49045 claims
GSKTrelegy Ellipta, Breo Ellipta$40$36,13137 claims
NovartisEntresto$40$31,14623 claims
Astellas Pharma US IncMyrbetriq$47$16,23616 claims
AbbVieCreon, Synthroid$19$6,82825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →